Ranbaxy's troubled relationship with the USFDA seems to have entered a new zone. Ranbaxy and the US health regulator are reportedly negotiating a settlement to lift a ban on the sale of the drugs produced at two of the company's plants in India, which could involve payments and fines exceeding $1 billion.
